Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
Figure 5
Growth of AML MNC ± drug treatment. Growth of untreated (…. dotted line), Ara-C treated (- - - dashed line) or CNDAC treated (— solid line) (a) PB and (b) BM AML cells from patients over the 35 day culture period, plotted as % survival relative to the number of cells initially plated. Drug treatment concentrations plotted are at 1 μM and 10 μM. *denotes P ≤ 0.05 as determined by the log rank test as compared to the survival curve of untreated cells.